ConductScience.org, home

Paper17517854

Rosiglitazone and cardiovascular risk.

Psaty BM and 1 other. N Engl J Med, 2007. Cited by 123 papers, by iCite.

Cite this record

ConductScience Library. Rosiglitazone and cardiovascular risk. Papers, record 17517854. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17517854

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Rosiglitazone and cardiovascular risk.
PubMed
Journal
N Engl J Med
PubMed
Year
2007
PubMed
Publication types
Editorial, Comment
PubMed
Citations, by iCite
123
iCite
Relative citation ratio, by iCite
2.99
iCite
Revised in PubMed
2026-01-28
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Psaty BMBruce M
2Furberg CDCurt D

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cardiovascular DiseasesMajor topic
Diabetes Mellitus, Type 2Major topic
Drug ApprovalMajor topic
Hypoglycemic AgentsMajor topic
Myocardial InfarctionMajor topic
ThiazolidinedionesMajor topic
Adverse Drug Reaction Reporting Systems
Clinical Trials, Phase IV as Topic
Humans
Meta-Analysis as Topic
Randomized Controlled Trials as Topic
Risk Assessment
Rosiglitazone
United States
United States Food and Drug Administration

Source PubMed

Download CSV of topics

Comments and corrections4

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in17551160Rosiglitazone--continued uncertainty about safety.https://conductscience.org/library/papers/17551160PubMed
Comment in17551161Rosiglitazone and cardiotoxicity--weighing the evidence.https://conductscience.org/library/papers/17551161PubMed
Comment in17806134Rosiglitazone and cardiovascular risk.https://conductscience.org/library/papers/17806134PubMed
Comment on17517853Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.https://conductscience.org/library/papers/17517853PubMed

Download CSV of comments and corrections

Cited by42

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.

PMIDTitleJournalYearIn PapersSource
41008970
Elucidating Key Components and Mechanisms Underlying the Synergistic Anti-Type 2 Diabetes Effect of Morus alba L. and Siraitia grosvenorii Combination: An Integrated In Vitro Enzymology, Untargeted Metabolomics, and Network Pharmacology Approach.
Antioxidants (Basel)2025https://conductscience.org/library/papers/41008970PubMed
38803898Chronotherapy involving rosiglitazone regulates the phenotypic switch of vascular smooth muscle cells by shifting the phase of TNF-α rhythm through triglyceride accumulation in macrophages.Heliyon2024https://conductscience.org/library/papers/38803898PubMed
38683294The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Adv Ther2024https://conductscience.org/library/papers/38683294PubMed
37514148Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy.Pharmaceutics2023https://conductscience.org/library/papers/37514148PubMed
37508471Exploring Rosiglitazone's Potential to Treat Alzheimer's Disease through the Modulation of Brain-Derived Neurotrophic Factor.Biology (Basel)2023https://conductscience.org/library/papers/37508471PubMed
36793276Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.Front Endocrinol (Lausanne)2023https://conductscience.org/library/papers/36793276PubMed
33623531Alismatis Rhizoma Triterpenes Alleviate High-Fat Diet-Induced Insulin Resistance in Skeletal Muscle of Mice.Evid Based Complement Alternat Med2021https://conductscience.org/library/papers/33623531PubMed
33116714Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity.Diabetes Metab Syndr Obes2020https://conductscience.org/library/papers/33116714PubMed
32855239Induction of UCP1 and thermogenesis by a small molecule via AKAP1/PKA modulation.J Biol Chem2020https://conductscience.org/library/papers/32855239PubMed
32024657Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.BMJ2020https://conductscience.org/library/papers/32024657PubMed
31885827Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes.Oxid Med Cell Longev2019https://conductscience.org/library/papers/31885827PubMed
27330371Drug safety: The concept, inception and its importance in patients' health.Saudi Pharm J2016https://conductscience.org/library/papers/27330371PubMed
26978569Disparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert.Med Care2016https://conductscience.org/library/papers/26978569PubMed
25826194Against vaccine assay secrecy.Hum Vaccin Immunother2015https://conductscience.org/library/papers/25826194PubMed
24897284Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes.Pharmacogenomics2014https://conductscience.org/library/papers/24897284PubMed
24563375Systematic reviews to ascertain the safety of diabetes medications.Curr Diab Rep2014https://conductscience.org/library/papers/24563375PubMed
24068766Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010.BMJ Open2013https://conductscience.org/library/papers/24068766PubMed
23738041Site-specific antioxidative therapy for prevention of atherosclerosis and cardiovascular disease.Oxid Med Cell Longev2013https://conductscience.org/library/papers/23738041PubMed
23695817Interpreting adverse signals in diabetes drug development programs.Diabetes Care2013https://conductscience.org/library/papers/23695817PubMed
23564465Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m(2): A Surgeon's Perspective.Obes Surg2013https://conductscience.org/library/papers/23564465PubMed

See all 42 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17517854

GET https://conductscience.org/api/papers/v1/17517854/cited_by?page=2